Neurological complications of infliximab

The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis (RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients who developed neurological disease closely as...

Full description

Saved in:
Bibliographic Details
Published inJournal of rheumatology Vol. 33; no. 5; p. 1018
Main Authors Jarand, Julie, Zochodne, Douglas W, Martin, Liam O, Voll, Christopher
Format Journal Article
LanguageEnglish
Published Canada 01.05.2006
Subjects
Aged
Aged, 80 and over
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Demyelinating Diseases - chemically induced
Demyelinating Diseases - pathology
Demyelinating Diseases - physiopathology
Female
Humans
Infliximab
Middle Aged
Nervous System - drug effects
Nervous System - pathology
Nervous System - physiopathology
Polyneuropathies - chemically induced
Polyneuropathies - pathology
Polyneuropathies - physiopathology
Online AccessGet more information

Cover

More Information
Summary:The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis (RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients who developed neurological disease closely associated with the use of infliximab, a monoclonal antibody that binds to and inactivates TNF-a. All had evidence of polyneuropathy, demyelinating in one and axonal in 2. One patient had a central nervous system syndrome. Physicians should be aware of these potential adverse effects when treating patients with infliximab.
ISSN:0315-162X